Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.

Hirayama, Takeshi

Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. [electronic resource] - Internal medicine (Tokyo, Japan) May 2018 - 1219-1227 p. digital

Publication Type: Journal Article

1349-7235

10.2169/internalmedicine.9479-17 doi


Aged
Anilides--therapeutic use
Antiviral Agents--therapeutic use
Carbamates--therapeutic use
Case-Control Studies
Cyclopropanes
Cytochrome P-450 CYP3A--metabolism
Drug Therapy, Combination
Female
Genotype
Hepatitis C--drug therapy
Hepatitis C, Chronic--drug therapy
Humans
Hydroxycholesterols--blood
Imidazoles--therapeutic use
Interferons--administration & dosage
Isoquinolines--therapeutic use
Lactams, Macrocyclic
Macrocyclic Compounds--therapeutic use
Male
Middle Aged
Proline--analogs & derivatives
Pyrrolidines
Ritonavir--therapeutic use
Sex Factors
Sulfonamides--therapeutic use
Treatment Failure
Valine--analogs & derivatives